BI 706039
Alternative Names: BI-706039Latest Information Update: 19 Jul 2021
At a glance
- Originator Boehringer Ingelheim
- Class Anti-inflammatories
- Mechanism of Action Receptor-interacting protein serine-threonine kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 19 Jul 2021 BI 706039 is available for licensing as of 19 Jul 2021. https://www.boehringer-ingelheim.com/partnering (Boehringer Ingelheim pipeline, July 2021)
- 21 May 2021 Pharmacodynamics data from a preclinical study in Inflammatory bowel disease presented at the Digestive Disease Week 2021 (DDW-2021)
- 01 May 2021 Preclinical trials in Inflammatory bowel diseases in Germany (PO)